BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Inventories: 124.06M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMRN Inventories Rankings
| Overall | 59th percentile | 1053 of 2596 |
| Sector | 79th percentile | 67 of 322 in Healthcare |
| Industry | 86th percentile | 9 of 69 in Biotechnology |
BMRN Inventories Range, Past 5 Years
| Minimum | 30.71M | Jun 2007 |
| Maximum | 130.12M | Dec 2011 |
| Average | 80.65M |
You may also be interested in these BMRN related companies
BMRN News
RT @TheEquitiesRoom: Stocks trading down to 20d support: $EIX $DRI $SWI $BMC $OPTR $BMRN $HSY < nice list
about 7 days ago by 1nvestor
about 7 days ago by 1nvestor
Five Stocks Hit 52-Week Highs $RDWR $CHDN $LL $BMRN $MTH http://stks.co/3rG6 My story via @TheStreet
about 12 days ago by azendrian
about 12 days ago by azendrian
$BMRN Insider Sale: $1.5M of stock sold by Bienaime Jean Jacques between May 11, 2012 - May 14, 2012 http://stks.co/3qP6
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
$BMRN Insider Sale: $1.6M of stock sold by Davis George Eric on May 11, 2012 http://stks.co/3qOj
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
Listen to $BMRN inc. at deutsche bank ag health care conference - live at 08:00 AM, ondemand after - http://stks.co/3jp6
about 19 days ago by earningscast
about 19 days ago by earningscast
BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer
May 08, 4:05PM Benzinga
May 08, 4:05PM Benzinga
$BMRN Insider Sale: $1.1M of stock sold by Bienaime Jean Jacques between May 1, 2012 - May 2, 2012 http://stks.co/3elV
about 25 days ago by MarketBrief
about 25 days ago by MarketBrief
BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 27, 3:10AM Seeking Alpha
Apr 27, 3:10AM Seeking Alpha
Listen to $BMRN Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3XW8
about 31 days ago by earningscast
about 31 days ago by earningscast
BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
Apr 26, 4:50PM Street Insider
Apr 26, 4:50PM Street Insider
$BMRN http://stks.co/3Njb $BMRN, Buy at trendline & 200 day ma support. Robust pipeline
about 41 days ago by Catalystrader
about 41 days ago by Catalystrader
UPDATE - UBS Initiates Coverage on BioMarin (BMRN) with a Buy; Accumulate on Pullback
Apr 12, 11:07AM Street Insider
Apr 12, 11:07AM Street Insider
$BMRN http://stks.co/3IgM Weekly triangle break down. Worth watch for new setup after new up correction http://stks.co/3IgN
about 47 days ago by xpertstocktrader
about 47 days ago by xpertstocktrader
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3DE1
about 54 days ago by MarketBrief
about 54 days ago by MarketBrief
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3C5Q
about 55 days ago by MarketBrief
about 55 days ago by MarketBrief
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3Amr
about 56 days ago by MarketBrief
about 56 days ago by MarketBrief
BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA
Mar 08, 9:02AM Benzinga
Mar 08, 9:02AM Benzinga
BioMarin (BMRN) Announces Completion of Enrollment for Phase 3 Study on GALNS
Mar 08, 9:02AM Street Insider
Mar 08, 9:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMR | 18.25 | -0.17 | -0.92% | 2.815B |
| BMO | 52.99 | -0.73 | -1.36% | 33.94B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BLC | 5.85 | -0.03 | -0.51% | 608.52M |
| BKYF | 23.80 | -0.23 | -0.96% | 177.31M |
| BKT | 7.52 | +0.00 | +0.00% | |
| BKSC | 11.64 | +0.19 | +1.66% | 51.80M |
| BKS | 17.23 | +0.19 | +1.11% | 1.037B |
| BKR | 22.63 | +0.01 | +0.04% | 215.89M |
